Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Microbiome Analysis Report
Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. Our microbiome analysis report provides a deep dive into the microbiome space.
GlobalData’s Microbiome Analysis report combines key opinion leader and payer insight with in-house analyst expertise to deliver a deep analysis into the microbiome space in immunology. It focuses on the development of therapies targeting the skin microbiome for treatment of acne, atopic dermatitis and psoriasis and on development of therapies targeting the gut microbiome for treatment of Crohn’s disease, UC, and IBS.
Stay ahead of the competition and get ahead with our report.
Small biotech leads the way in microbiome-targeted therapeutics; however large pharma companies such as J&J have made it a priority to partner with biotech companies and academic labs to further development of microbiome-targeted therapeutics in immunology.
There are 10 pipeline therapies in clinical development targeting the gut microbiome for treatment of Crohn’s Disease, UC and IBS. For treatment of acne, AD and PsO however, there are only three pipeline therapies in clinical development targeting the skin microbiome.